The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.

November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the Boston Scientific Watchman device to warfarin in patients with nonvalvular atrial fibrillation found that the first composite co-primary endpoint of stroke, systemic embolism (SE), or cardiovascular/unexplained death did not achieve noninferiority. However, the second co-primary endpoint of post-procedure ischemic stroke/SE did achieve noninferiority.
The B. Braun Sequent Please drug-eluting balloon.
DARE trial results presented at TCT 2017 show drug coated balloons are equal to the Xience stent in treating restenosis.

November 2, 2017 — The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (Drug-eluting bAlloon for in-stent Restenosis) multicenter, randomized clinical trial evaluated the performance of the B. Braun Sequent Please drug-eluting balloon (DEB) vs. the Abbott Xience everolimus-eluting stent (EES) in patients with ISR. The study found the DEB was non-inferiority to the drug-eluting stent (DES).

November 2, 2017 — Crossing the occlusion with a guidewire is often the most challenging part of chronic total occlusion (CTO) percutaneous coronary intervention (PCI), and there is debate about the optimal initial crossing strategy during the procedure.

OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 2 in Denver. The results provide fresh insights into the optimal treatment of patients with acute coronary syndrome (ACS) using the COMBO Dual Therapy Stent.

The double kissing (DK) crush two-stent technique was associated with a lower rate of target lesion failure at one year compared with provisional stenting (PS) in the treatment of true distal bifurcation lesions of the left main artery, according to a large-scale randomized trial.

Analytics 4 Life announced it will be presenting new clinical data on the company's ongoing Coronary Artery Disease Learning and Algorithm Development (CADLAD) study at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 scientific symposium, Oct. 29-Nov. 2 in Denver.

James A. Brink, M.D., FACR, chair of the American College of Radiology (ACR) Board of Chancellors, met with the House Committee on Science, Space and Technology Subcommittee on Energy to urge more research on low-dose medical radiation effects to inform future safety practices. He also told the Committee that medical imaging and radiation oncology save lives.

Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.

November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strategy of culprit lesion-only percutaneous coronary intervention (PCI) reduces the composite of 30-day mortality and/or severe renal failure in patients with multivessel disease and cardiogenic shock complicating acute myocardial infarction.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now